Rocket Pharmaceuticals has achieved a significant milestone with the accelerated approval of Kresladi (marnetegragene autotemcel) by the US Food and Drug Administration (FDA).This gene therapy is designed for pediatric patients suffering from severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic immunodeficiency caused by mutations in the ITGB2 gene that prevent effective white blood cell function.
Sources:
insideprecisionmedicine.comfda.govSevere LAD-I is classified as an ultra-rare condition, impacting approximately one in one million births globally.Without treatment, children with this disorder face recurrent, life-threatening infections, leading to high mortality rates in early childhood.
Sources:
insideprecisionmedicine.comnewsroom.ucla.eduKresladi represents the first FDA-approved gene therapy targeting this serious condition, which has historically relied on aggressive infection management and allogeneic stem cell transplants from matched donors, a challenging option given the rarity of suitable donors.
Sources:
fda.govir.rocketpharma.comThe therapy involves extracting a patient's own hematopoietic stem cells, which are then genetically modified using a lentiviral vector to include a functional copy of the ITGB2 gene.After undergoing intensive conditioning, these modified cells are infused back into the patient, potentially providing a lifelong correction of their immune deficiency.
Sources:
insideprecisionmedicine.comcellgenetherapyreview.comThe approval process for Kresladi was not without its hurdles.Rocket faced challenges, including a hold on its Danon gene therapy trial due to a patient death and a Complete Response Letter citing manufacturing issues prior to the eventual approval of Kresladi.
Sources:
insideprecisionmedicine.comcellgenetherapyreview.comHowever, the accelerated approval pathway allows Rocket to market Kresladi while still requiring the company to conduct post-marketing studies to verify the clinical benefits of the therapy.
Sources:
fda.govir.rocketpharma.comDr Gaurav Shah, CEO of Rocket Pharmaceuticals, expressed optimism about this approval, stating, "The approval of Kresladi represents an important milestone for the severe LAD-I community." He highlighted the collaborative efforts of patients, families, and regulatory bodies in advancing research for this ultra-rare disease.
Sources:
ir.rocketpharma.comcellgenetherapyreview.comThe FDA's decision was influenced by clinical trial results that demonstrated significant improvements in biomarkers indicative of immune function, such as neutrophil CD18 and CD11a surface expression.
Sources:
fda.govir.rocketpharma.comThese biomarkers are crucial for the immune system's ability to respond to infections.In a clinical trial conducted by Dr Donald Kohn at UCLA, patients showed marked improvements in immune reconstitution, significantly reducing the incidence of severe infections and hospitalizations.
Source:
newsroom.ucla.eduKresladi's approval also comes with a Rare Pediatric Disease Priority Review Voucher, which Rocket intends to sell to enhance its financial flexibility.
Sources:
insideprecisionmedicine.comir.rocketpharma.comAlthough Kresladi's market potential may be limited due to the rarity of LAD-I, it positions Rocket Pharmaceuticals for continued growth in the gene therapy space, particularly as the company explores treatments for other rare diseases.
Sources:
insideprecisionmedicine.comnewsroom.ucla.eduThe approval of Kresladi is not only a breakthrough for patients with severe LAD-I but also a pivotal moment in the field of gene therapy.It may serve as a model for developing therapies for other rare genetic disorders, as the scientific community recognizes the importance of commercial investment in making such treatments available.
Source:
newsroom.ucla.eduAs Rocket Pharmaceuticals prepares to launch Kresladi, the future holds promise for affected families, offering hope for improved quality of life through innovative gene therapy solutions.
